MCE - Delayed Quote EUR

Oryzon Genomics S.A. (ORY.MC)

Compare
1.7420 -0.0280 (-1.58%)
At close: 5:35 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ORY.MC

Recent News: ORY.MC

View More
ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder

ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder
ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress

ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress
ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder

ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia

ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat with Additional “Decision to Grant” Communications

ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat with Additional “Decision to Grant” Communications
ORYZON to Provide Corporate Progress Updates at Several Events in September

ORYZON to Provide Corporate Progress Updates at Several Events in September
ORYZON reports financial results and corporate update for half-year ending June 30, 2024

ORYZON reports financial results and corporate update for half-year ending June 30, 2024
ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan

ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan
ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders

ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders
ORYZON Announces Presentation of Final Data From PORTICO, Vafidemstat’s Global Phase IIb Trial in Borderline Personality Disorder, at the 37th ECNP Annual Conference

ORYZON Announces Presentation of Final Data From PORTICO, Vafidemstat’s Global Phase IIb Trial in Borderline Personality Disorder, at the 37th ECNP Annual Conference
ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at EHA-2024

ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at EHA-2024
View More

Related Tickers